Immortalization and characterization of a new canine mammary tumour cell line FR37-CMT

L. R. Raposo, C. Roma-Rodrigues, P. Faísca, M. Alves, J. Henriques, M. C. Carvalheiro, M. L. Corvo, P. V. Baptista, A. J. Pombeiro, A. R. Fernandes

Research output: Contribution to journalArticle

4 Citations (Scopus)


Here we describe the establishment of a new canine mammary tumour (CMT) cell line, FR37-CMT that does not show dependence on female hormonal signaling to induce tumour xenografts in NOD-SCID mice. FR37-CMT cell line has a stellate or fusiform shape, displays the ability to reorganize the collagen matrix, expresses vimentin, CD44 and shows the loss of E-cadherin which is considered a fundamental event in epithelial to mesenchymal transition (EMT). The up-regulation of ZEB1, the detection of phosphorylated ERK1/2 and the downregulation of DICER1 and miR-200c are also in accordance with the mesenchymal characteristics of FR37-CMT cell line. FR37-CMT shows a higher resistance to cisplatin (IC50>50 µM) and to doxorubicin (IC50>5.3 µM) compared with other CMT cell lines. These results support the use of FR37-CMT as a new CMT model that may assist the understanding of the molecular mechanisms underlying EMT, CMT drug resistance, fostering the development of novel therapies targeting CMT.

Original languageEnglish
Pages (from-to)952-967
Number of pages16
JournalVeterinary and Comparative Oncology
Issue number3
Publication statusPublished - 1 Sep 2017


  • canine mammary tumours
  • cisplatin
  • doxorubicin
  • epithelial to mesenchymal transition
  • miRNAs

Fingerprint Dive into the research topics of 'Immortalization and characterization of a new canine mammary tumour cell line FR37-CMT'. Together they form a unique fingerprint.

Cite this